Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
about
Other targeted drugs in melanomaTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?CIViC databaseFirst-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaThe broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin.Targeting drivers of melanoma with synthetic small molecules and phytochemicals.Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancerAtg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven MelanomaAntitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.Targeting protein kinase-b3 (akt3) signaling in melanoma.Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway.Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS- Mutant Cancers.
P2860
Q54903526-A6B3110A-082B-4C29-A7ED-6FA8D3670C2CQ54903541-EF1C77A8-1FDD-4D27-AAB3-8FFAFD45867CQ54903549-743F7F06-DA56-48C1-BD22-BF55094AD6D8Q54903550-DCB2B807-0C58-4C07-AB89-D08D986C8675Q54903553-F4817BDC-819E-4299-8DE7-FE2CDB98F025Q54903562-FDEBFEA2-EBBD-48F5-A128-B76551C381A6Q54903568-827B18FF-522B-4F89-BB68-C214A0F3B019Q54903573-D1E80D29-6041-47F2-A0EE-9B1BD85D6B7AQ54903574-7B0ABB2D-17C9-4FA0-92CB-45F83B7AD5DFQ54903582-B60BF499-A8B9-4A40-8C67-F8FC31927D55Q54903592-8515A8BB-B47E-4533-8A0F-CD82CA4882DDQ95984236-47BBD05C-2164-476D-AE28-5BD9F6246AEFQ95984246-2B3FC818-8CC6-42A3-9F91-EED674155AFAQ95984250-F0B7B0E6-F73E-4641-AB51-5459766FC290Q95984253-47F06039-00D4-43C2-822D-7BB3AB4883AEQ95984256-425AA1C4-8FB2-428C-9FFF-A81836774970Q95984285-13A311DB-A818-4145-929F-5D5AEBD803C8Q95984288-1FAA5181-6016-4D78-9308-0C10DCD6A865Q95984289-5A4DDA83-047E-474D-99E5-D41D1E3CB042Q95984290-3ED74134-3B62-4337-A043-0237BAE96ED6Q95984293-AEEBFE24-AA18-49CB-BD14-96CF56CE16E1Q95984294-F8C7E13E-2AA3-4479-B77F-21FB27B485B6Q95984297-0B0AE1F0-CC2F-48E0-8597-6ED593A8A730Q95984299-E8CE362F-E1F7-457A-B2E9-7033978645C7
P1343
Q26775594-8A95A846-F36B-4DE2-9C53-B40A1FC6AB09Q26782222-BFC6F9C3-CB5E-4234-A84D-6F82F502F520Q27612411-C62D2730-CA8A-4DB4-AEBE-27E9DAE11F7BQ27853088-B585715E-DBE0-4D6B-A0F4-8D5347EB9828Q30277902-FD0604E4-B2D9-46F2-BB61-363E3AE270C8Q34515007-9DEF8879-6751-4AC7-8E49-9CE6EBD9D432Q34786402-809F6735-D514-429C-81E0-F295EC56B476Q35597799-C758B3FF-0503-4C00-855F-312B761C2C3CQ35619558-1A69DC37-03E9-4D6C-BE68-5DAC5E221F71Q36010837-BB077038-54D3-465B-9BE2-B82CB44FFC2AQ36141097-93C86487-1D8E-4568-A5E4-2E34B6D2BC92Q37176575-D3229BD4-2534-44DA-A0F4-910A2B7E52F7Q37655023-0279C7BF-7D7B-4931-B1F2-78AEAA1F43B5Q37705948-8B7FCBA2-F71B-4E4F-AB8A-C55F920B4F9EQ38910539-260BC817-1F7D-4D08-9BD8-D2F20D782AC1Q38964277-0683F0DF-1B54-4723-949A-9962E2241E49Q38983353-24C32CF4-1A63-4B73-A59A-87C7080D2E5CQ39074281-F67D61C5-E810-4D1E-9B74-67FDA7A44C64Q42068332-82544F3E-59B4-408D-8200-E31EC86BBA56Q47130626-4830FF13-BEF5-4BE6-B809-CCBFF7F2E2D3Q48155250-0ACB357F-69DA-45D1-9BF1-4E1D023EF72CQ48583910-160582E2-20EB-423F-9180-BB2B129B74AA
P2860
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@ast
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@en
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@nl
type
label
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@ast
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@en
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@nl
altLabel
Effects of AKT inhibitor thera ...... to BRAF inhibition in melanoma
@en
prefLabel
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@ast
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@en
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@nl
P2093
P2860
P3181
P356
P1433
P1476
Effects of AKT inhibitor thera ...... o BRAF inhibition in melanoma.
@en
P2093
Amanda Lassen
Begonya Comin-Anduix
Deborah Jl Wong
Lidia Robert
Michael Cerniglia
Mohammad Atefi
P2860
P2888
P3181
P356
10.1186/1476-4598-13-83
P50
P577
2014-04-16T00:00:00Z
P5875
P6179
1046715855